Abstract:Objective To evaluate the efficacy,safety and tolerance of continuous erythropoietin receptor activator (CERA) once every 2 weeks intravenous injection on anemia correction in dialysis patients compared to Epoetin-3 (EPO-β) administration.Methods An open-label,randomized,parallel,active-control and multi-center clinical trial was performed.All the hemodialysis or peritoneal dialysis patients with chronic renal anemia who had not been treated with erythropoiesis-stimulating agents (ESAs)for at least 8 weeks before entering the treatment phase were randomized (1∶1) to receive either CERA once every 2 weeks intravenous administration (CERA group,n=132) or intravenous EPO-β three times weekly (EPO group,n=133) for 24 weeks including 16-week correction period and 8-week efficacy evaluation period.At week 25,the patients who reached the target Hb (defined as Hb≥ 110 g/L and increase in Hb≥10 g/L from baseline without red blood cell transfusion during the 24 weeks after the first dose) were kept on CERA or EPO-β treatment regimen for the subsequent 28 weeks to evaluate the long-term safety and tolerability.The starting dose of CERA was 0.4 μg/kg.Two primary endpoints were (1) the Hb response rate during the first 24 weeks; and (2)the mean change in Hb between the baseline and the evaluation periods (week 17 to week 24).Results Totally 232 patients (87.5％) completed the first 24-week treatment and 198 patients (74.7％) completed the whole study treatment (52 weeks).The response rate in CERA group during the first 24 weeks was 87.12％[95％ CI(80.2％ to 92.3％)].Since the lower limit of the 95％CI was greater than 60％ (P ＜ 0.01),CERA once every 2 weeks intravenous administration was considered as effective in correction of renal anemia.The difference between CERA group and EPO group in mean change of Hb from evaluation periods to baseline in the per-protocol (PP) population was-4.7 g/L [95％CI (-7.38 g/L to-1.92 g/L)].Since the lower limit of 95％CI was greater than the pre-defined noninferiority margin-7.5 g/L (P=0.0205),CERA was considered as non-inferior to EPO in the maintenance of Hb after anemia correction.The Hb level remained stable during the subsequent 28-week extension period in both CERA and EPO groups.During the whole study period,the overall safety findings were similar in CERA and EPO groups,50.0％ and 54.6％ of patients experienced at least one adverse event (AE) respectively.The findings from AEs were in accordance with the characteristics of the studied population.Conclusions Intravenous CERA once every 2 weeks is safe and effective for correcting anemia in dialysis patients.Treatment with CERA once every 2 weeks is also non-inferior to 3 times weekly EPO in maintaining the Hb level after the correction.In general,long-term intravenous administration of CERA is well tolerated by dialysis patients with chronic renal anemia.

[Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].

Effect of Early Correction of Anemia with Erythropoietin on Left Ventricular Mass in Predialysis Patients:A Multi-Center Trial

Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO)

Effect of Epoetin Alfa on Left Ventricular Hypertrophy in Pre-dialysis Patients

Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome

Restoration of Normal Hemoglogbin Level in Patients with Sever Chronic Congestive Heart Failure Accompanied by Anemia

Roxadustat Versus Erythropoietin: The Comparison of Efficacy in Reversing Ventricular Remodeling in Dialysis Patients with Anaemia

Efficacy,safety and Tolerance of Continuous Erythropoietin Receptor Activator Intravenous Administration on Anemia Correction in Dialysis Patients with Chronic Renal Anemia

[The Efficacy and Safety of Continuous Erythropoietin Receptor Activator in Dialytic Patients with Chronic Renal Anemia: an Open, Randomized, Controlled, Multi-Center Trial].

Research of high and low dose H-rHuEPO on uremic anemia in the maintenance heamodialysis patients

MO756: Roxadustat Versus Erythropoietin: Comparison of Efficacy in Reversing Ventricular Remodeling in Dialysis Patients with Anemia

Effects of r-HuEPO on RBC immunity in CRF patients

Effect of Hematocrit Levels on Cardiac Function and Structure in Hemodialysis Patients

Roxadustat reduces left ventricular mass index compared to rHuEPO in haemodialysis patients in a randomized controlled trial

Effects of Erythropoietin on Cardiac Function in Patients with Chronic Heart Failure Accompanied by Anemia

[Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients]

The Effects of Anemia-Correction on Cardiac Structure and Function in Maintenance Hemodialysis Patients

A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia

Analysis of L-carnitine Combined with rhEPO for the Treatment of 30 Patients with Renal Anemia

Long-Term Effects of Oral L-Carnitine Supplementation on Anemia in Chronic Hemodialysis

Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease?